396 related articles for article (PubMed ID: 31253381)
41. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
42. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
43. A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.
Tadmor T; Braester A; Najib D; Aviv A; Herishanu Y; Yuklea M; Shvidel L; Rahimi-Levene N; Ruchlemer R; Arad A; Fogl C; Henig C; Barak M; Magal L; Polliack A; Townsend K;
Eur J Haematol; 2019 Oct; 103(4):335-341. PubMed ID: 31278876
[TBL] [Abstract][Full Text] [Related]
44. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
[TBL] [Abstract][Full Text] [Related]
45. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios.
Bradwell AR; Harding SJ; Fourrier NJ; Wallis GL; Drayson MT; Carr-Smith HD; Mead GP
Clin Chem; 2009 Sep; 55(9):1646-55. PubMed ID: 19617289
[TBL] [Abstract][Full Text] [Related]
46. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
47. Free light chains and heavy/light chains in monitoring POEMS patients.
Altinier S; Proko K; Zaninotto M; Ciubotaru D; Seguso M; Varagnolo M; Lessi F; Briani C; Adami F; Plebani M
Clin Chem Lab Med; 2016 Jun; 54(6):1065-71. PubMed ID: 27071150
[TBL] [Abstract][Full Text] [Related]
48. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
[TBL] [Abstract][Full Text] [Related]
49. IgMκ-IgMλ pair quantitation in the clinical laboratory practice.
Sarto C; Cappellini F; Giagnacovo M; Brambilla P
Clin Biochem; 2018 Jan; 51():56-60. PubMed ID: 27838406
[TBL] [Abstract][Full Text] [Related]
50. Analysis of patients with γ-heavy chain disease by the heavy/light chain and free light chain assays.
Kaleta E; Kyle R; Clark R; Katzmann J
Clin Chem Lab Med; 2014 May; 52(5):665-9. PubMed ID: 24327529
[TBL] [Abstract][Full Text] [Related]
51. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies.
Harding SJ; Mead GP; Bradwell AR; Berard AM
Clin Chem Lab Med; 2009; 47(3):302-4. PubMed ID: 19676141
[TBL] [Abstract][Full Text] [Related]
52. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
[TBL] [Abstract][Full Text] [Related]
53. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
[TBL] [Abstract][Full Text] [Related]
54. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies].
Lakomy D; Lemaire-Ewing S; Denimal D; Bastie JN; Lafon I; Caillot D
Ann Biol Clin (Paris); 2013; 71(2):157-63. PubMed ID: 23587579
[TBL] [Abstract][Full Text] [Related]
56. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
[TBL] [Abstract][Full Text] [Related]
57. Immunoglobulin heavy and light chain isotypes in multiple myeloma patients.
Ansari NA; Owais M; Usha
Asian Pac J Cancer Prev; 2007; 8(4):593-6. PubMed ID: 18260735
[TBL] [Abstract][Full Text] [Related]
58. Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures.
Bergón E; Miravalles E
Clin Chem Lab Med; 2008; 46(8):1156-62. PubMed ID: 18605957
[TBL] [Abstract][Full Text] [Related]
59. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
60. High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma.
Kraj M; Kruk B; Lech-Marańda E; Warzocha K; Prochorec-Sobieszek M
Leuk Lymphoma; 2015; 56(12):3348-56. PubMed ID: 25860239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
